Summary The latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2019, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.
Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 6, 9, 5, 5, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029
Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
With a population of more than 1 billion, China is the worldâ€™s largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro...
Opportunity Analyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche’s Esbriet and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval...
Commercial Real Estate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.